Press ReleasesCantourage UK Brings Together Pharma's Uganda-Grown Medical Cannabis To...

Cantourage UK Brings Together Pharma’s Uganda-Grown Medical Cannabis To The United Kingdom

-

CANTOURAGE UK and Israeli medical cannabis producer Together Pharma (TASE: TGTR) have brought the first Ugandan medical cannabis to the United Kingdom. From today, patients throughout the UK will have access to two of Together Pharma’s high-THC genetics: Glueberry OG® and Power Plant.

Cantourage UK, a subsidiary of Berlin-based European medical cannabis leader Cantourage, has successfully imported the dried flower products from Germany. Cantourage UK will offer Together Pharma’s high-THC, non-irradiated medical cannabis flowers to patients immediately through Cantourage Clinic.

Together Pharma is the only cultivator of medical cannabis in Uganda. Its Ugandan farm extends over some approx. 30,000 sqm Greenhouses and has a full production capacity of more than 15 tonnes annually, including a range of innovative cultivars which will be introduced into the UK’s medical cannabis market over the next few months.

As of today, Cantourage has signed contracts with over 20 leading cultivators from 13 different countries. Together Pharma is the first company to launch products grown in Africa via Cantourage’s Fast Track Access Platform.

Niall Ivers, COO at Cantourage UK: “We’re delighted to be extending our successful partnership with Together Pharma into the UK. Together Pharma is a market leader in the Israeli domestic market with extensive knowledge and international experience in delivering high-quality, great-value medicines to patients. We’re confident the introduction of these first two varieties will assist in building a sustainable eco-system for UK patients.”

Nir Sosinsky, Managing Director of Together Pharma, added: “Our extended partnership with Cantourage UK is extremely exciting for Together Pharma and a new stage in the expansion of our global reach. It strengthens our position in the UK and Europe, while at the same time underpinning our commitment to Uganda’s cannabis industry, which holds great future potential for the country. The United Kingdom is an extremely important market for us. We are glad that our medical-grade cannabis flowers are being made available through Cantourage UK and Cantourage Clinic, allowing for a reliable supply to the benefit of patients across the country.”

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you